AA
LKFT

ALPS Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

ALPS Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.96M Buy
65,523
+11,862
+22% +$337K 0.01% 529
2026
Q1 		$1.61M Sell
53,661
-130
-0.2% -$4.3K 0.01% 448
2025
Q4 		$1.76M Buy
53,791
+21,886
+69% +$707K 0.01% 416
2025
Q3 		$1.11M Sell
31,905
-3,473
-10% -$111K 0.01% 497
2025
Q2 		$990K Sell
35,378
-12,908
-27% -$346K 0.01% 501
2025
Q1 		$1.21M Sell
48,286
-5,169
-10% -$131K 0.01% 432
2024
Q4 		$1.47M Buy
53,455
+3,557
+7% +$99.2K 0.01% 394
2024
Q3 		$1.44M Sell
49,898
-1,553
-3% -$42.3K 0.01% 413
2024
Q2 		$1.27M Buy
51,451
+4,739
+10% +$134K 0.01% 413
2024
Q1 		$1.5M Buy
46,712
+990
+2% +$36.8K 0.01% 399
2023
Q4 		$1.86M Sell
45,722
-2,590
-5% -$95.3K 0.01% 342
2023
Q3 		$1.67M Buy
48,312
+191
+0.4% +$7.43K 0.01% 350
2023
Q2 		$1.96M Buy
48,121
+5,066
+12% +$207K 0.02% 311
2023
Q1 		$1.66M Sell
43,055
-1,581
-4% -$65K 0.01% 325
2022
Q4 		$1.98M Buy
44,636
+8,433
+23% +$355K 0.02% 299
2022
Q3 		$1.54M Sell
36,203
-2,961
-8% -$152K 0.01% 358
2022
Q2 		$2.19M Sell
39,164
-27,998
-42% -$1.66M 0.02% 306
2022
Q1 		$4.17M Sell
67,162
-9,118
-12% -$558K 0.05% 139
2021
Q4 		$4.21M Buy
+76,280
New +$3.98M 0.05% 160
2019
Q2 		– Sell
-87,116
Closed -$10.3M – 887
2019
Q1 		$10.3M Buy
87,116
+11,045
+15% +$1.11M 0.07% 118
2018
Q4 		$6.98M Sell
76,071
-14,777
-16% -$1.5M 0.05% 134
2018
Q3 		$10.2M Buy
90,848
+17,459
+24% +$1.84M 0.07% 121
2018
Q2 		$6.76M Buy
73,389
+5,234
+8% +$508K 0.04% 143
2018
Q1 		$6.8M Buy
68,155
+11,845
+21% +$1.28M 0.05% 124
2017
Q4 		$5.28M Buy
56,310
+6,265
+13% +$593K 0.04% 138
2017
Q3 		$5.09M Buy
50,045
+4,177
+9% +$365K 0.04% 143
2017
Q2 		$3.51M Buy
45,868
+6,200
+16% +$521K 0.02% 153
2017
Q1 		$3.42M Sell
39,668
-4,641
-10% -$334K 0.02% 155
2016
Q4 		$2.84M Sell
44,309
-14,473
-25% -$891K 0.02% 160
2016
Q3 		$3.8M Sell
58,782
-5,993
-9% -$338K 0.03% 152
2016
Q2 		$3.59M Buy
64,775
+20,901
+48% +$1.05M 0.03% 141
2016
Q1 		$1.83M Sell
43,874
-7,519
-15% -$349K 0.02% 155
2015
Q4 		$3.23M Buy
+51,393
New +$2.63M 0.03% 146

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
DO
denkapparat Operations Berlin, Germany $306M AUM 40.46% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

ALPS Advisors's LKFT Position: Q2 2026 in Review

ALPS Advisors increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 22% in Q2 2026, buying an estimated $337K and bringing the position to 65,523 shares worth $1.96M. The position accounts for 0.01% of the portfolio, ranked #529.

ALPS Advisors first reported a position in LKFT in Q4 2015 and has held it in 33 quarters since. The position peaked at $10.3M in Q1 2019. 24 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

  • ALPS Advisors held 65,523 shares of Lakefront Biotherapeutics American Depositary Shares worth $1.96M as of Q2 2026.
  • ALPS Advisors bought 11,862 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $337K.
  • Lakefront Biotherapeutics American Depositary Shares made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #529 holding.
  • ALPS Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2015 and has held it in 33 quarters since.
  • ALPS Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $10.3M in Q1 2019.
  • 24 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.